Skip to main content

Security report for angelinipharma.ch

Angelini Pharma Zug S.p.A. · Healthcare · Switzerland

Low risk. 3 critical or high findings in GDPR outside view, Email security and 1 other check.

Security score

82/100

Risk levelLow

0–100, higher is better. How it is calculated

Angelini Pharma Zug S.p.A. is a well-established pharmaceutical division of Angelini Industries based in Switzerland, with a history spanning over 100 years. The company operates internationally with a focus on mental health, epilepsy, and consumer healthcare, employing approximately 15 people at its Zug location and over 3,000 worldwide. The website reflects a professional and consistent brand image, targeting healthcare professionals, patients, and partners. The business model centers on pharmaceutical research, development, and commercialization, positioning Angelini Pharma as a leader in the European healthcare market. Technically, the website employs modern JavaScript libraries such as jQuery, Slick Carousel, and Magnific Popup, alongside Piwik PRO for analytics with privacy-conscious features. The site is mobile-optimized with good SEO and accessibility basics, hosted on secure HTTPS infrastructure. Performance is moderate, with room for optimization. From a security perspective, the site enforces HTTPS and implements cookie consent mechanisms aligned with GDPR. However, explicit security policies and incident response contacts are not published, and security headers are not evident. No vulnerabilities or exposed sensitive data were detected. The WHOIS data is consistent with the business claims, showing no privacy protection or suspicious patterns, supporting the domain's legitimacy. Overall, Angelini Pharma's website demonstrates a strong business credibility and privacy compliance posture, with good technical implementation and security practices. Strategic improvements could focus on publishing dedicated security policies and enhancing security headers to further strengthen trust and compliance.

Scanned

NIS2 and GDPR posture

GDPR outside view
68/ 100 · Medium
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

3 findings rated critical or high. Fix these first.

  1. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • High

      No Cookie Consent Banner found

      GDPR requires explicit consent for non-essential cookies

      What to do: Implement a cookie consent banner that appears on first visit

  2. Email security

    SPF, DKIM and DMARC stop others sending email that looks like it comes from your domain, a common route to phishing and invoice fraud.

    • High

      No DMARC record found

      DMARC provides email authentication and reporting

      What to do: Add DMARC record: "v=DMARC1; p=none; rua=mailto:dmarc@yourdomain.com"

  3. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

Need hands-on remediation? Email guard@offseq.com

Keep watching angelinipharma.ch

This scan found 13 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
82
Security headers
90
Email security
65
DNS health
85
Network security
100
GDPR outside view
68
Average
82

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Angelini Pharma is positioned as a key player in the pharmaceutical sector, with a broad European footprint and a diversified portfolio focusing on brain health, epilepsy, and consumer healthcare. The company leverages its century-long heritage and parent company Angelini Industries to maintain market leadership. Its business model emphasizes research and development, supported by a network of subsidiaries across multiple countries. The website's content and linked domains reflect a mature partnership ecosystem and a clear focus on healthcare professionals and patients. Growth indicators include active social media engagement and recognized certifications such as Top Employer Europe 2025. The company’s digital presence supports its strategic objectives by providing comprehensive information and facilitating partner and customer engagement.

Security posture

The website exhibits a mature security posture with mandatory HTTPS and a cookie consent mechanism that respects user privacy and GDPR requirements. The use of Piwik PRO analytics with anonymization options indicates a privacy-aware approach to data collection. However, the absence of a publicly available security policy and incident response contact channels limits transparency and readiness perception. Security headers such as Content-Security-Policy and X-Frame-Options are not detected, representing an area for improvement. No vulnerabilities or exposed sensitive data were found in the HTML content. Overall, the security maturity is good but could be enhanced by formalizing security governance documentation and implementing additional HTTP security headers.

Recommendations

  1. Publish a dedicated security policy page outlining security practices and controls.
  2. Provide explicit incident response contact information (e.g., security@ or abuse@ email).
  3. Implement and enforce HTTP security headers such as Content-Security-Policy, X-Frame-Options, and Strict-Transport-Security.
  4. Regularly audit and update third-party libraries to mitigate potential vulnerabilities.
  5. Enhance accessibility features and performance optimizations to improve user experience.

Contact details published on the site

Addresses
Legal name
Angelini Pharma Zug S.p.A.
Registration number
APPIAN: 18745
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Angelini Pharma Zug S.p.A.
Description
Angelini Pharma Zug S.p.A. is the pharmaceutical division of Angelini Industries in Switzerland. The group has over 100 years of history and operates in 20 countries with over 3,000 employees worldwide. The Zug location employs approximately 15 people. The company focuses on mental health, epilepsy, and consumer healthcare.
Key services
Pharmaceutical research, Product development, Commercialization of health solutions
Content quality
good
Branding
consistent

Technology

Stack
jQuery 3.7.1, jQuery Validation, Slick Carousel, Magnific Popup, Flip.js, Piwik PRO analytics
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • Cookie consent mechanism implemented
  • No exposed sensitive data in HTML
  • Use of analytics anonymization option

Analytics and tracking

Services
Piwik PRO
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Piwik PRO
Marketing tools
Piwik PRO
Transparency
good

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is professionally designed with clear navigation and consistent branding.
  2. Comprehensive privacy and cookie policies with consent mechanisms are implemented.
  3. Strong presence of social media links and external partner domains.
  4. No signs of malicious content or security blocking.
  5. Use of modern JavaScript libraries and analytics tools with privacy options.
  6. Contact information is present but no explicit security or incident response policies found.
Technical notes

Notes

The website uses a modern JavaScript-based front-end stack including jQuery, Slick Carousel, Magnific Popup, and Flip.js for UI components and interactivity. Analytics are handled by Piwik PRO, which supports privacy compliance. Fonts are served from a dedicated Angelini Industries domain and Google Cloud Storage, indicating a controlled asset delivery. The site is hosted with HTTPS and integrates cookie consent scripts for compliance. Performance is moderate with asynchronous loading of scripts, but some lazy loading images and multiple external dependencies could be optimized. No CMS is explicitly detected, suggesting a custom or proprietary solution. The technical infrastructure supports a professional and compliant web presence but could benefit from enhanced security headers and performance tuning.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with angelinipharma.ch. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review angelinipharma.ch.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.